Comparative Pharmacology
Head-to-head clinical analysis: MPI DTPA KIT CHELATE versus PULMOLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DTPA KIT CHELATE versus PULMOLITE.
MPI DTPA KIT - CHELATE vs PULMOLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DTPA (diethylenetriaminepentaacetic acid) chelates paramagnetic metal ions (e.g., gadolinium) to form stable complexes that alter T1 relaxation times during MRI, enhancing contrast.
PULMOLITE is a leukotriene receptor antagonist (LTRA) that selectively and competitively inhibits the cysteinyl leukotriene (CysLT1) receptor in the human airway, thereby reducing bronchoconstriction, mucus secretion, and eosinophilic infiltration.
Adult: 3-4 mCi (111-148 MBq) intravenously as a single dose for renal imaging.
Adults: 200 mg intravenously every 12 hours over 30 minutes.
None Documented
None Documented
The terminal elimination half-life is approximately 1.7 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to >20 hours in severe renal impairment.
Terminal elimination half-life: 12 hours (range 10–14 h) in adults with normal renal function (CrCl >90 mL/min); prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Renal excretion accounts for >95% of the administered dose via glomerular filtration; less than 2% is excreted in feces.
Primarily renal (80%) as unchanged drug; 15% fecal via biliary excretion; 5% metabolized.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical